Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype of multiple myeloma (MM). EMM is frequently associated with high-risk cytogenetics, but their complex genomic architecture is largely unexplored. We used whole-genome optical mapping (Saphyr, Bionano Genomics) to analyse the genomic architecture of CD138+ cells isolated from bone-marrow aspirates from an unselected cohort of newly diagnosed patients with EMM (n=4) and intramedullary MM (n=7). Large intrachromosomal rearrangements (>5 Mbp) within chromosome 1 were detected in all EMM samples. These rearrangements, predominantly deletions with/without inversions, encompassed hundreds of genes and led to changes in the gene copy number on large regions of...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Introduction: In multiple myeloma (MM), karyotypic events such as translocations between the IGH loc...
Multiple myeloma (MM) is the second most common hematologic malignancy. The disease is characterized...
Abstract Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype o...
Extramedullary multiple myeloma (or extramedullary disease, EMD) is an aggressive form of multiple m...
Symptomatic multiple myeloma (MM) is preceded by an indolent expansion of clonal plasma cells, known...
Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multi...
marrowplasma cells that accounts for 10% of all hematological malignancies.The broad clinical spectr...
Multiple myeloma (MM) is a malignancy of post-germinal centre B-cells whose pathogenesis is only par...
SummaryTo identify genetic events underlying the genesis and progression of multiple myeloma (MM), w...
Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying...
Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multi...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Introduction. Multiple myeloma (MM) is characterized by deep genomicinstability that involves both p...
Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM). We report th...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Introduction: In multiple myeloma (MM), karyotypic events such as translocations between the IGH loc...
Multiple myeloma (MM) is the second most common hematologic malignancy. The disease is characterized...
Abstract Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype o...
Extramedullary multiple myeloma (or extramedullary disease, EMD) is an aggressive form of multiple m...
Symptomatic multiple myeloma (MM) is preceded by an indolent expansion of clonal plasma cells, known...
Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multi...
marrowplasma cells that accounts for 10% of all hematological malignancies.The broad clinical spectr...
Multiple myeloma (MM) is a malignancy of post-germinal centre B-cells whose pathogenesis is only par...
SummaryTo identify genetic events underlying the genesis and progression of multiple myeloma (MM), w...
Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying...
Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multi...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Introduction. Multiple myeloma (MM) is characterized by deep genomicinstability that involves both p...
Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM). We report th...
Multiple Myeloma (MM) represents a heterogeneous and complex hematological cancer, where karyotypic ...
Introduction: In multiple myeloma (MM), karyotypic events such as translocations between the IGH loc...
Multiple myeloma (MM) is the second most common hematologic malignancy. The disease is characterized...